Trefoil family factor proteins and uses thereof
View Patent ↗The invention provides for methods for treating an inflammatory disease of the digestive system in a subject by administering a trefoil family molecule. The invention provides for methods for treating a digestive system cancer in a subject by administering a trefoil family molecule. The invention provides for methods for cell proliferation in a subject by administering a trefoil family molecule.
1. A method of treating a subject who has a digestive system cancer consisting of administering to the subject a TFF2 protein, or a nucleic acid which encodes a TFF2 protein, so as to decrease tumor associated myeloid-derived suppressor cell proliferation and thereby treat the subject.
2. The method of claim 1 , wherein the method consists of administering to the subject a nucleic acid which encodes a TFF2 protein.
3. The method of claim 2 , wherein the nucleic acid is delivered as a viral vector.
4. The method of claim 2 , wherein the nucleic acid comprises a nucleotide sequence set forth in SEQ ID NO: 4.
5. The method of claim 1 , wherein the digestive system cancer is selected from the group consisting of small intestine cancer, large intestine cancer, colon cancer, rectal cancer, and anal cancer.
6. The method of claim 1 , wherein the tumor associated myeloid-derived suppressor cell expresses a MDSC-specific surface marker.
7. The method of claim 1 , wherein the tumor associated myeloid-derived suppressor cell does not express a MDSC-specific surface marker.
8. The method of claim 6 , wherein the MDSC-specific surface marker is selected from the group consisting of (1) Grl1, CD11b, or a combination thereof; and (2) CD14, CD15, CD33, or a combination thereof.
9. The method of claim 7 , wherein the MDSC-specific surface marker that the tumor associated myeloid-derived suppressor cell does not express is HLA-DR.
10. A method of treating a subject who has a digestive system cancer consisting of administering to the subject a TFF2 protein to which a CTP domain is fused so as to decrease tumor associated myeloid-derived suppressor cell proliferation and thereby treat the subject.